Shanghai Allist Pharmaceuticals Management
Management criteria checks 2/4
Shanghai Allist Pharmaceuticals' CEO is Jinhao Du, appointed in Sep 2022, has a tenure of 2.33 years. directly owns 2.4% of the company’s shares, worth CN¥636.44M. The average tenure of the management team and the board of directors is 2.3 years and 5.2 years respectively.
Key information
Jinhao Du
Chief executive officer
CN¥3.5m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.3yrs |
| CEO ownership | 2.4% |
| Management average tenure | 2.3yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
CEO
Jinhao Du (70 yo)
2.3yrs
Tenure
CN¥3,530,700
Compensation
Mr. Jinhao Du serves as Chairman of the Board at Shanghai Allist Pharmaceuticals Co., Ltd. since November 28, 2019 and serves as its General Manager since September 14, 2022.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 2.3yrs | CN¥3.53m | 2.4% CN¥ 636.4m | |
| Financial Director | 1.8yrs | CN¥1.19m | no data | |
| Marketing Manager | 1.8yrs | CN¥1.83m | no data | |
| Deputy GM & Director | 5.2yrs | CN¥2.06m | no data | |
| Board Secretary | 4.8yrs | CN¥958.90k | no data |
2.3yrs
Average Tenure
49yo
Average Age
Experienced Management: 688578's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 5.2yrs | CN¥3.53m | 2.4% CN¥ 636.4m | |
| Deputy GM & Director | 1.8yrs | CN¥2.06m | no data | |
| Director | 5.2yrs | no data | no data | |
| Independent Director | 5.2yrs | CN¥96.00k | no data | |
| Director | 2.8yrs | no data | no data | |
| Director | 5.2yrs | no data | 8.99% CN¥ 2.4b | |
| Independent Director | 5.2yrs | CN¥96.00k | no data | |
| Employee Representative Supervisor | 1.8yrs | no data | no data |
5.2yrs
Average Tenure
42yo
Average Age
Experienced Board: 688578's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 06:18 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Allist Pharmaceuticals Co., Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Feifei Xu | China Merchants Securities Co. Ltd. |
| Zhu Chen | Citic Securities Co., Ltd. |
| Tan Huan Gan | Citic Securities Co., Ltd. |